

Piramal Offers Commercial Scale ADC Manufacture

Mumbai, June 2011: Based on an expanded and FDA-approved manufacturing suite at its Grangemouth, Scotland facility, Piramal Healthcare has begun commercial scale ADC (antibody drug conjugate) manufacturing for leading players in the anti-cancer drug space.

Piramal Healthcare is one of the few contract manufacturers operating in ADCs and the first contract supplier of commercial ADCs anywhere in the world. Expanded last year, Piramal's dedicated ADC process development and GMP production facility is one of three ADC production suites at the site. Following inspection, US FDA approval for manufacturing was confirmed earlier this year. The company works with 11 of the top 16 global ADC clients.

ADCs are targeted therapies designed to deliver a drug payload to cancer cells while minimising the adverse effects on normal healthy cells. Several ADC-based therapies are in late-phase trials, with about a dozen in Phase I and 20+ at the pre-clinical stage. Grangemouth has a notable track record in both ADC development and scale-up production. Piramal's facility is one of only a handful in the contract manufacturing sector to offer the needed combination of expertise in handling highly potent compounds, conventional pharma synthesis and bioprocessing multi-scale capabilities at a single, fully integrated production site.

To date, Grangemouth has made over 300 ADC batches from 2g - 500g scales, across a range of over 30 different ADC NCEs (new chemical entities). "Commercial scale manufacture is another exciting ADC milestone and the culmination of over a decade of ADC experience at our Grangemouth facility", commented Nicole Tingley, Director of Business Development for Antibody Drug Conjugates. "As an increasing number of these drugs move through clinical phases we're confident that the range and depth of our manufacturing development experience will continue to add value to both existing customer partnerships and advancement of new ADC candidates", she added.

As part of a continuing upgrade programme to support its ADC portfolio, Piramal opened a new US \$400k. Quality Control lab suite at Grangemouth earlier this year. The development combines a number of previously separate capabilities into a single suite. The latest upgrade



spend is additional to direct investment in ADC facilities of more than US \$800k. over the last four years

About Piramal Healthcare

Piramal Healthcare is a part of the Piramal Enterprises Ltd. Led by Ajay G. Piramal, the Piramal Group is one of India's foremost business conglomerates. Emerging from a rich textile industry lineage, the Piramal Group has exemplified diversification by foraying into a myriad of industries that encompass healthcare, drug discovery and research, glass, real estate and financial services.

Piramal Enterprises, Piramal Life Sciences, Piramal Glass and Piramal Realty are the flagship companies that operate within these sectors. The Piramal Group truly demonstrates a global footprint with its products and services being exported to over 100 countries, its international income contributing to greater than 70% of the Group's revenues and more than 15 nationalities being represented amongst its employees.